机构：[1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy四川大学华西医院[2]Department of Urinary Surgery, West China Hospital, West China School of Medicine, Sichuan University四川大学华西医院[3]Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China四川大学华西医院[4]Department of Mathematics and Statistics, University of Calgary, Calgary, AB T2N 1N4, Canada[5]Laboratory of Cell and Molecular Biology and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021, P.R. China
Progesterone receptor membrane component 1 (PGRMC1) and Na+/K+‑ATPase α1 subunit (ATP1A1) are two proteins associated with the clinical prognosis of renal cell carcinoma (RCC) and RCC cell proliferation. However, the two proteins have been previously studied independently, and their combined influence on the clinical outcome of RCC remains unclear. The present study suggests that the combined expression levels of PGRMC1 and ATP1A1 (PGRMC1/ATP1A1) are associated with the clinical prognosis of RCC patients. RCC patients with low PGRMC1/positive ATP1A1 levels exhibited the best overall survival (OS) outcomes (103.08±1.85 months). The high PGRMC1/negative ATP1A1 group demonstrated the worst prognosis (73.1±8.87 months). The low PGRMC1/positive ATP1A1 group had the highest 7‑year OS rate (92.3%). The high PGRMC1/negative ATP1A1 group had the lowest 7‑year OS rate (46.7%). Although PGRMC1 and ATP1A1 both act on AKT phosphorylation in RCC cells, their expression levels are independent of each other. Moreover, the synergistic suppressive roles of PGRMC1 downregulation combined with ATP1A1 upregulation exhibit more efficient tumor inhibition potentials on RCC cells. Therefore, combined assessment of the two biomarkers (PGRMC1/ATP1A1) shows enhanced prognostic ability for RCC.
基金：
The present study was financially supported by the grants from
the National 863 High Tech Foundation (no. 2014AA020608),
the National Key Basic Research Program of China
(nos. 2013CB911303 and 2011CB910703), the National
Natural Sciences Foundation of China (nos. 31470810
and 30970654), the Science and Technology Department of
Sichuan Province (no. 2017JY0232) and the Health and Family
Planning Commission of Sichuan Province (no. 17ZD045).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|3 区医学
小类|4 区肿瘤学
最新[2023]版：
大类|3 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy
共同第一作者：
通讯作者：
通讯机构：[1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy[*1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, 17 Section 3, People's South Road, Chengdu, Sichuan 610041, P.R. China
推荐引用方式(GB/T 7714)：
YU HE,PENG ZHANG,DAN ZHANG,et al.Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma.[J].Oncology reports.2018,40(3):1467-1476.doi:10.3892/or.2018.6541.
APA：
YU HE,PENG ZHANG,DAN ZHANG,ZIJING XIA,XIXI WANG...&SHUFANG LIANG.(2018).Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma..Oncology reports,40,(3)
MLA：
YU HE,et al."Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma.".Oncology reports 40..3(2018):1467-1476
